Travere Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Travere Therapeutics, Inc. (NASDAQ: TVTX) is a commercial-stage biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare kidney and metabolic diseases. The company's primary commercial engine is FILSPARI (sparsentan), a first-in-class dual endothelin angiotensin receptor antagonist (DEARA). FILSPARI is FDA-approved to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression, and to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. Beyond its nephrology franchise, Travere is developing pegtibatinase (TVT-058), an investigational enzyme replacement therapy for classical homocystinuria (HCU), a rare metabolic disorder.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Maximizing the commercial potential of FILSPARI following its full FDA approval in IgA Nephropathy (IgAN) and its landmark April 2026 approval in Focal Segmental Glomerulosclerosis (FSGS). This includes expanding the field sales team and driving broad physician adoption.
Expected impact: Aims to capture a substantial portion of the estimated $3B+ potential peak sales opportunity for FILSPARI in the U.S.
Advancing the clinical development of pegtibatinase, a novel investigational human enzyme replacement therapy for classical homocystinuria (HCU), following the restart of the Phase 3 HARMONY study.
Expected impact: Establishes a potential first-in-class disease-modifying therapy for classical HCU, addressing a significant unmet medical need.
Integrating civorebrutinib, a potential best-in-class oral, covalent reversible BTK inhibitor, into Travere's rare kidney disease portfolio to target primary membranous nephropathy (PMN), immune-mediated FSGS, and minimal change disease (MCD).
Expected impact: Diversifies the pipeline beyond FILSPARI and pegtibatinase, adding a 'pipeline-in-a-product' asset with multi-indication potential.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secures exclusive development and commercialization rights for civorebrutinib (EVER001) in all markets outside of China and certain East/Southeast Asian territories, bolstering Travere's rare kidney disease pipeline.
Terms: Everest Medicines receives an upfront payment of $112.5 million and is eligible to receive up to approximately $1.03 billion in clinical development, regulatory, and commercial milestones across up to five indications, plus tiered high-single-digit to double-digit royalties on future net sales.
Chugai holds the license to develop and commercialize sparsentan (FILSPARI) for the treatment of IgAN in Japan.
Terms: Travere remains eligible to receive potential milestone payments related to the regulatory process and net sales achievements, as well as tiered royalties.
CSL Vifor is responsible for the commercialization of FILSPARI in Europe, having launched the therapy in Germany, Austria, Switzerland, Luxembourg, and the UK.
Terms: Travere is eligible to receive additional market access and sales-based milestones, alongside royalties on net sales.